DBV Technologies | DBVT

DBV Technologies traded at $1.63 this Thursday March 23rd, decreasing $0.01 or 0.61 percent since the previous trading session. Looking back, over the last four weeks, DBV Technologies lost 19.85 percent. Over the last 12 months, its price rose by 1.88 percent. Looking ahead, we forecast DBV Technologies to be priced at 1.45 by the end of this quarter and at 1.32 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1.63
Daily Change
-0.61%
Yearly
1.88%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Acadia Pharmaceuticals 18.26 -0.24 -1.30% -32.74%
Alnylam Pharmaceuticals 189.68 -0.06 -0.03% 15.87%
Amarin 1.54 0.01 0.33% -53.63%
BioCryst Pharmaceuticals 8.06 0.12 1.45% -51.71%
BioMarin Pharmaceutical 89.86 -0.22 -0.24% 11.10%
DBV Technologies 1.63 -0.01 -0.61% 1.88%
Esperion Therapeutics 1.54 0.08 5.48% -69.80%
Galectin Therapeutics 1.95 -0.02 -1.02% 10.17%
Halozyme Therapeutics 33.54 0.68 2.07% -13.38%
Intercept Pharmaceuticals 13.52 -0.07 -0.52% -19.81%
Incyte Corp 72.28 0.02 0.03% -7.56%
Insmed 16.41 0.15 0.89% -28.11%
Ionis Pharmaceuticals 33.78 -1.52 -4.29% -8.52%
Neurocrine Biosciences 95.17 0.02 0.02% 1.19%
PTC Therapeutics 46.34 -0.02 -0.03% 23.76%
Ultragenyx Pharmaceutical 37.10 -0.18 -0.48% -46.33%
Sarepta Therapeutics 127.30 -1.81 -1.40% 58.25%
United Therapeutics 214.41 1.42 0.67% 19.87%

Indexes Price Day Year
USND 11831 115.72 0.99% -16.64%

DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.